The University of Southampton
University of Southampton Institutional Repository

Early use of infliximab improves outcomes In patients with Rheumatoid Arthritis associated sight threatening ocular surface inflammation

Early use of infliximab improves outcomes In patients with Rheumatoid Arthritis associated sight threatening ocular surface inflammation
Early use of infliximab improves outcomes In patients with Rheumatoid Arthritis associated sight threatening ocular surface inflammation
Purpose: : Monoclonal antibody therapy such as Infliximab is currently advocated as a second line therapy in treating rheumatoid arthritis (RA) when there is failure to control disease with more than one disease modifying anti-α rheumatic drug (DMARD). However, whether it has a similar role in rheumatoid arthritis associated non-infectious ocular surface inflammatory is unclear. Current data on the use of anti-TNF-α therapy in this group of patients is limited. The purpose of this study is to evaluate the efficacy and safety of standard DMARD alone or in combination with Infliximab at inducing and maintaining disease remission in patients with sight threatening ocular surface disease. Methods: : Retrospective case series of 16 patients with RA was undertaken at a single unit. Equal numbers had either a step up in standard DMARD therapy or the addition of Infliximab to induce remission. Stabilization of melt, perforation, surgical intervention, time to remission and treatment related morbidity were the measured outcomes. Results: : Infliximab induced faster remission, within 4 weeks (1-8 weeks) than with standard DMARD alone, 9 months (4-20 weeks) (t-test, p<0.002). Infliximab treated patients were more likely to be steroid independent. Two RA associated deaths occurred in standard DMARD therapy group. Conclusions: : The addition of Infliximab to standard DMARD therapy achieved rapid and full remission of inflammatory disease. Infliximab infusions were safe, well tolerated and maintained disease control in the longer term.This data supports the early and regular use of Infliximab in rheumatoid associated ocular inflammatory disease.
0146-0404
Hanifudin, Abdul
7eab2d90-9c9f-4901-aaa4-b9ff36cbf2a8
McAlister, James C
ac0e5043-8109-4ae3-916f-38617812dd18
Konstantopoulos, Aristides
c54185a9-1ef3-4b6d-91a3-38de444cc4fb
Ardjomand, Navid
2991b041-58a0-41dd-a254-27bbf7220685
Anderson, David F.
de3b2d61-3698-4c8f-adcf-604483666fda
Hossain, Parwez
563de5fc-84ad-4539-9228-bde0237eaf51
Hanifudin, Abdul
7eab2d90-9c9f-4901-aaa4-b9ff36cbf2a8
McAlister, James C
ac0e5043-8109-4ae3-916f-38617812dd18
Konstantopoulos, Aristides
c54185a9-1ef3-4b6d-91a3-38de444cc4fb
Ardjomand, Navid
2991b041-58a0-41dd-a254-27bbf7220685
Anderson, David F.
de3b2d61-3698-4c8f-adcf-604483666fda
Hossain, Parwez
563de5fc-84ad-4539-9228-bde0237eaf51

Hanifudin, Abdul, McAlister, James C, Konstantopoulos, Aristides, Ardjomand, Navid, Anderson, David F. and Hossain, Parwez (2011) Early use of infliximab improves outcomes In patients with Rheumatoid Arthritis associated sight threatening ocular surface inflammation. Investigative Ophthalmology & Visual Science, 52 (14).

Record type: Meeting abstract

Abstract

Purpose: : Monoclonal antibody therapy such as Infliximab is currently advocated as a second line therapy in treating rheumatoid arthritis (RA) when there is failure to control disease with more than one disease modifying anti-α rheumatic drug (DMARD). However, whether it has a similar role in rheumatoid arthritis associated non-infectious ocular surface inflammatory is unclear. Current data on the use of anti-TNF-α therapy in this group of patients is limited. The purpose of this study is to evaluate the efficacy and safety of standard DMARD alone or in combination with Infliximab at inducing and maintaining disease remission in patients with sight threatening ocular surface disease. Methods: : Retrospective case series of 16 patients with RA was undertaken at a single unit. Equal numbers had either a step up in standard DMARD therapy or the addition of Infliximab to induce remission. Stabilization of melt, perforation, surgical intervention, time to remission and treatment related morbidity were the measured outcomes. Results: : Infliximab induced faster remission, within 4 weeks (1-8 weeks) than with standard DMARD alone, 9 months (4-20 weeks) (t-test, p<0.002). Infliximab treated patients were more likely to be steroid independent. Two RA associated deaths occurred in standard DMARD therapy group. Conclusions: : The addition of Infliximab to standard DMARD therapy achieved rapid and full remission of inflammatory disease. Infliximab infusions were safe, well tolerated and maintained disease control in the longer term.This data supports the early and regular use of Infliximab in rheumatoid associated ocular inflammatory disease.

This record has no associated files available for download.

More information

Published date: April 2011

Identifiers

Local EPrints ID: 448107
URI: http://eprints.soton.ac.uk/id/eprint/448107
ISSN: 0146-0404
PURE UUID: af55562b-a4d5-41b3-b411-2392cd8275d0
ORCID for Parwez Hossain: ORCID iD orcid.org/0000-0002-3131-2395

Catalogue record

Date deposited: 01 Apr 2021 15:59
Last modified: 17 Mar 2024 03:04

Export record

Contributors

Author: Abdul Hanifudin
Author: James C McAlister
Author: Aristides Konstantopoulos
Author: Navid Ardjomand
Author: David F. Anderson
Author: Parwez Hossain ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×